In the early 21st century the bioprocessing industry fretted about a production crisis that never happened. Concern arose a decade ago that downstream purification facilities would not be adequate to ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...